Drugs / panitumumab-IRDye800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02415881 | Aug 2016 → Nov 2019 | head and neck cancer | Eben Rosenthal | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | panitumumab-IRDye800CW | “an antibody-dye conjugate (panitumumab-IRDye800CW) as primary outcome” PMID 33168818 ↗ Nov 2020 |
| Route | Intravenous | “was intravenously administered to patients with head and neck squamous cell carcinoma (HNSCC) scheduled to undergo surgery of curative intent” PMID 33078373 ↗ Oct 2020 |
| Target | EGFR | “an anti-epidermal growth factor receptor (EGFR) contrast agent” PMID 31421471 ↗ Aug 2019 |